AnalystsMatt PhippsMatt Phipps's Stock Forecasts
AnalystsMatt Phipps
Analyst Ranking
Top 28%
#1550 out of 5511 analysts
Average Return
+8%
Win Rate
33%8 out of 24
Risk vs Reward
Poor
Good
Matt Phipps's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Climb Bio IncCLYM | +613.33% | $1.95 | $13.91 | 2025-10-16 - 2026-09-15 | Buy |
Context Therapeutics IncCNTX | +184.17% | $0.83 | $2.37 | 2025-04-21 - 2026-04-21 | Buy |
Tenax Therapeutics IncTENX | +119.94% | $3.46 | $7.61 | 2024-09-30 - 2025-09-30 | Buy |
Genmab AGMAB | +35.14% | $20.26 | $27.38 | 2025-03-11 - 2026-03-11 | Buy |
Merus NvMRUS | +24.52% | $23.29 | $29.00 | 2021-04-08 - 2022-04-07 | Buy |
Matt Phipps Analyst Color
Get additional color on Matt Phipps's coverage of popular stocks
Matt Phipps's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Tenax Therapeutics IncTENX | 2 | Hold | N/A | N/A | Downgrades | a month ago |
Abbvie IncABBV | 1 | Strong Buy | N/A | N/A | Maintains | 2 months ago |
Zura Bio LtdZURA | 1 | Buy | N/A | N/A | Initiates Coverage On | 2 months ago |
Evommune IncEVMN | 2 | Hold | N/A | N/A | Downgrades | 3 months ago |
Compass Therapeutics IncCMPX | 1 | Buy | N/A | N/A | Initiates Coverage On | 8 months ago |
Dynavax Technologies CorpDVAX | 1 | Hold | N/A | N/A | Downgrades | 9 months ago |
Kezar Life Sciences IncKZR | 3 | Hold | N/A | N/A | Downgrades | a year ago |
Climb Bio IncCLYM | 1 | Buy | N/A | N/A | Initiates Coverage On | a year ago |
Insmed IncINSM | 1 | Buy | N/A | N/A | Initiates Coverage On | a year ago |
Mink Therapeutics IncINKT | 2 | Hold | N/A | N/A | Downgrades | a year ago |
Jasper Therapeutics IncJSPR | 2 | Hold | N/A | N/A | Downgrades | a year ago |
Context Therapeutics IncCNTX | 1 | Buy | N/A | N/A | Initiates Coverage On | a year ago |
Xencor IncXNCR | 1 | Buy | N/A | N/A | Initiates Coverage On | a year ago |
Genmab AGMAB | 2 | Buy | N/A | N/A | Upgrades | 2 years ago |
Keros Therapeutics IncKROS | 1 | Hold | N/A | N/A | Downgrades | 2 years ago |
Upstream Bio IncUPB | 1 | Buy | N/A | N/A | Initiates Coverage On | 2 years ago |
Nucana PLCNCNA | 1 | Hold | N/A | N/A | Downgrades | 2 years ago |
Amgen IncAMGN | 1 | Buy | N/A | N/A | Upgrades | 2 years ago |
Cullinan Therapeutics IncCGEM | 1 | Buy | N/A | N/A | Initiates Coverage On | 2 years ago |
Bristol Myers Squibb CoBMY | 1 | Hold | N/A | N/A | Downgrades | 3 years ago |
Chinook Therapeutics IncKDNY | 1 | Hold | N/A | N/A | Downgrades | 3 years ago |
Newamsterdam Pharma Co NvNAMS | 1 | Buy | N/A | N/A | Initiates Coverage On | 4 years ago |
Janux Therapeutics IncJANX | 1 | Buy | N/A | N/A | Initiates Coverage On | 4 years ago |
Phasebio Pharmaceuticals IncPHASQ | 1 | Hold | N/A | N/A | Downgrades | 4 years ago |
Rein Therapeutics IncRNTX | 1 | Hold | N/A | N/A | Downgrades | 4 years ago |
Calithera Biosciences IncCALA | 1 | Hold | N/A | N/A | Downgrades | 5 years ago |
Tempest Therapeutics IncTPST | 1 | Buy | N/A | N/A | Initiates Coverage On | 5 years ago |
Biogen IncBIIB | 1 | Buy | N/A | N/A | Upgrades | 5 years ago |
Imagenebio IncIMA | 1 | Buy | N/A | N/A | Initiates Coverage On | 5 years ago |
Merus NvMRUS | 1 | Buy | N/A | N/A | Initiates Coverage On | 5 years ago |
F Star Therapeutics IncFSTX | 1 | Buy | N/A | N/A | Initiates Coverage On | 5 years ago |
Palvella Therapeutics IncPVLA | 1 | Buy | N/A | N/A | Initiates Coverage On | 9 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.